A Phase III, double-blind, randomised, multicenter trial comparing the safety and efficacy of fixed dose combination tablets of arterolane maleate and piperaquine phosphate (PQP) with Coartem® (artemether-lumefantrine tablets) in patients with acute uncomplicated Plasmodium falciparum malaria

Trial Profile

A Phase III, double-blind, randomised, multicenter trial comparing the safety and efficacy of fixed dose combination tablets of arterolane maleate and piperaquine phosphate (PQP) with Coartem® (artemether-lumefantrine tablets) in patients with acute uncomplicated Plasmodium falciparum malaria

Completed
Phase of Trial: Phase III/IV

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Arterolane/piperaquine (Primary) ; Artemether/lumefantrine
  • Indications Falciparum malaria
  • Focus Therapeutic Use
  • Sponsors Ranbaxy Laboratories
  • Most Recent Events

    • 02 Mar 2016 New trial record
    • 12 Feb 2016 Results published in the Clinical Infectious Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top